Alpha 2.0
Login Register
» Articles » PMID: 22567079

Rare Diseases: Canada's "research Orphans"

Overview
Journal Open Med
Date 2012 May 9
PMID 22567079
Citations 2
Authors
Samir Gupta
Affiliations
Soon will be listed here.
Citing Articles

Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.

Rawson N Orphanet J Rare Dis. 2017; 12(1):59.

PMID: 28330479 PMC: 5363033. DOI: 10.1186/s13023-017-0611-7.

Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.

Paulden M, Stafinski T, Menon D, McCabe C Pharmacoeconomics. 2014; 33(3):255-69.

PMID: 25412735 PMC: 4342524. DOI: 10.1007/s40273-014-0235-x.

References
1.
Rados C . Orphan products: hope for people with rare diseases. FDA Consum. 2004; 37(6):10-5. View
2.
Gericke C, Riesberg A, Busse R . Ethical issues in funding orphan drug research and development. J Med Ethics. 2005; 31(3):164-8. PMC: 1734115. DOI: 10.1136/jme.2003.007138. View
3.
Taruscio D, Vittozzi L, Stefanov R . National plans and strategies on rare diseases in Europe. Adv Exp Med Biol. 2010; 686:475-91. DOI: 10.1007/978-90-481-9485-8_26. View
4.
Lavandeira A . Orphan drugs: legal aspects, current situation. Haemophilia. 2002; 8(3):194-8. DOI: 10.1046/j.1365-2516.2002.00643.x. View
5.
Haffner M . Adopting orphan drugs--two dozen years of treating rare diseases. N Engl J Med. 2006; 354(5):445-7. DOI: 10.1056/NEJMp058317. View